Ikena Halts IK-930 TEAD Inhibitor Program

Ikena Oncology discontinued development of IK-930, a TEAD1-selective Hippo pathway inhibitor, on May 28, 2024. The decision followed a review of disappointing Phase 1 clinical data and a shift in strategic priorities toward the company’s MEK-RAF molecular glue IK-595. Ikena reduced its workforce by 53% alongside the announcement.

The Hippo signaling pathway, which regulates organ size and cell growth, is frequently dysregulated in mesothelioma due to mutations in the NF2 tumor suppressor gene. When NF2 is lost, the transcriptional co-activators YAP and TAZ become hyperactive, driving cancer cell proliferation through TEAD transcription factors. IK-930 was designed to directly inhibit TEAD, blocking this oncogenic signaling cascade. In the Phase 1 dose-escalation study (NCT05228015), however, early data from November 2023 showed no confirmed remissions in the advanced solid tumor cohort, which included patients with NF2-mutated mesothelioma.

Understanding the Hippo-YAP-TEAD Pathway

The Hippo pathway is one of the most commonly disrupted signaling networks in mesothelioma. In normal tissue, the NF2 gene (also called Merlin) activates the Hippo pathway, which restrains cell growth by keeping the YAP and TAZ co-activators inactive. In mesothelioma, NF2 mutations or deletions disable Hippo signaling, allowing YAP and TAZ to enter the nucleus and activate TEAD transcription factors that drive uncontrolled cell growth. NF2 loss occurs in roughly 40% to 50% of pleural mesotheliomas, making it one of the most common genetic alterations in the disease alongside BAP1 and CDKN2A.

This makes the Hippo pathway an attractive therapeutic target, and IK-930 represents the first clinical-stage drug to directly inhibit TEAD function.

Trial Background and Discontinuation

The Phase 1 dose-escalation study evaluated IK-930 in patients with advanced solid tumors harboring Hippo pathway alterations, including a cohort of people with mesothelioma with NF2 mutations.

Study Design:

• First-in-human, open-label Phase 1 trial (NCT05228015)
• Oral, once-daily dosing
• Dose escalation to establish safety and a recommended Phase 2 dose
• Expansion cohorts for NF2-mutated tumors, including mesothelioma

Why Ikena Halted the Program:

According to Ikena’s May 2024 announcement, the discontinuation decision was based on a review of available clinical data from the ongoing Phase 1 trial, the company’s cash position (roughly $157 million as of March 31, 2024), and a strategic choice to prioritize IK-595. Formal response rates in the mesothelioma cohort were never published. ClinicalTrials.gov lists the trial as active but not recruiting, consistent with wind-down. Treatment may continue for patients deriving benefit, and the company has said it is evaluating strategic options, including potential partnerships for IK-930 combinations.

Why TEAD Inhibitors Still Matter for Mesothelioma

Even with IK-930 off the table, the TEAD inhibitor class remains important for mesothelioma for several connected reasons. First, this class addresses a key driver mutation. Unlike many cancers where targeted therapies exist for common mutations, mesothelioma has had few targetable genetic alterations, and NF2 loss is one of the most common events in mesothelioma pathogenesis. Second, the approach is a classic synthetic lethality strategy: NF2-mutant tumors become uniquely dependent on YAP/TAZ-TEAD signaling for survival, so blocking TEAD exploits that dependency. Third, TEAD inhibitors may combine well with chemotherapy, checkpoint inhibitors like nivolumab and ipilimumab, and other targeted agents such as CDK4/6 and mTOR inhibitors. Fourth, TEAD inhibitors under development are oral medications, which matters for quality of life across long treatment courses.

The Science Behind YAP/TAZ-TEAD Signaling

The Hippo pathway controls tissue growth during development and maintains organ size in adults. Its core components include upstream kinases (MST1/2 and LATS1/2) that form a cascade phosphorylating YAP and TAZ to mark them for degradation. NF2, also called Merlin, is a tumor suppressor that activates the Hippo kinase cascade. When unphosphorylated, the YAP/TAZ co-activators enter the nucleus, where they partner with the TEAD1-4 transcription factors to activate genes that drive proliferation, survival, and stem cell-like properties.

When NF2 is lost in mesothelioma:

1. The Hippo kinase cascade is disabled
2. YAP/TAZ accumulate in the nucleus
3. YAP/TAZ bind to TEAD factors
4. Pro-growth genes are activated
5. Cancer cells proliferate unchecked

IK-930 was designed to block the final step, preventing YAP/TAZ from activating TEAD even when they reach the nucleus. The mechanism remains scientifically valid. Ikena’s decision to discontinue reflected the specific performance of this molecule in its Phase 1 trial, not a broader failure of the TEAD strategy.

Where the Program Stands

With IK-930 wound down, the most advanced TEAD inhibitor program in mesothelioma is Vivace Therapeutics’ VT3989, which showed a 32% response rate, 86% disease control, and 40-week median progression-free survival in 22 patients at the optimized dose at ESMO 2025. Novartis separately halted enrollment in its TEAD inhibitor IAG933 in late 2025. IK-595, Ikena’s MEK-RAF molecular glue, is a separate program that is not a TEAD inhibitor and is being developed for RAS-pathway cancers.

What Patients Should Know

For people with mesothelioma:

• Ask your oncologist about NF2/Merlin status in your tumor
• Inquire whether molecular profiling has been performed
• Discuss eligibility for ongoing TEAD inhibitor trials such as VT3989
• Consider tissue re-biopsy if original testing didn’t include comprehensive genomic profiling

Questions to ask your doctor:

• Does my tumor have NF2 mutations or Hippo pathway alterations?
• Am I eligible for clinical trials of TEAD inhibitors?
• What molecular testing has been done on my tumor?
• How do targeted therapies fit into my treatment plan?

Other Hippo-Targeted Therapies in Development

IK-930 was not the only TEAD inhibitor in development. Other programs include:

• VT3989 (Vivace Therapeutics): Currently the most advanced TEAD inhibitor, headed to Phase 3 in 2026
• IAG933 (Novartis): Enrollment halted in late 2025 per the company, citing tolerability and antitumor activity
• Multiple preclinical candidates from academic and industry labs

The ongoing activity in this space reflects the strong biological rationale for targeting the Hippo pathway in mesothelioma and other NF2-altered cancers.

What the IK-930 Wind-Down Means

IK-930’s discontinuation is a reminder that Phase 1 data can look reasonable on safety while still falling short on efficacy. For years, researchers have known that NF2 loss is central to mesothelioma biology, but developing drugs that could exploit this knowledge has proved challenging.

Larger trials of other TEAD inhibitors, including VT3989, will determine whether this class delivers meaningful clinical benefit in mesothelioma. The approximately half of patients whose tumors harbor Hippo pathway alterations remain a biologically rational population for continued study.

Related Articles

• Mesothelioma Genetics and Mutations
• Targeted Therapy for Mesothelioma
• Current Clinical Trials
• Molecular Profiling for Mesothelioma